

**EFFECTIVE DATE:** 02|15|2016  
**POLICY LAST UPDATED:** 10|02|2018

## OVERVIEW

Radiotherapy (RT) is an integral component in the treatment of breast and lung cancers. Intensity-modulated radiotherapy (IMRT) has been proposed as a method of RT that allows adequate RT to the tumor while minimizing the radiation dose to surrounding normal tissues and critical structures.

## MEDICAL CRITERIA

### BlueCHiP for Medicare and Commercial Products

#### Breast

Intensity-modulated radiotherapy may be considered medically necessary as a technique to deliver whole-breast irradiation in patients receiving treatment for left-sided breast cancer after breast conserving surgery when all the following criteria is met:

- Significant cardiac radiation exposure cannot be avoided using alternative radiation techniques;
- IMRT dosimetry demonstrates significantly reduced cardiac target volume radiation exposure;
  - The target volume coverage results in cardiac radiation exposure that is expected to be greater than or equal to 25 Gy to 10 cm<sup>3</sup> or more of the heart ( $V_{25} \geq 10 \text{ cm}^3$ ) with 3D-CRT, despite the use of a complex positioning device (such as Vac-Lok™); and
  - With the use of IMRT, there is a reduction in the absolute heart volume receiving 25 Gy or higher by at least 20% (e.g., volume predicted to receive 25 Gy by 3D RT is 20 cm<sup>3</sup>, and the volume predicted by IMRT is  $\leq 16 \text{ cm}^3$ ).

IMRT may be considered medically necessary in individuals with large breasts, greater than 500 cm<sup>3</sup> when the following criteria is met:

- Treatment planning with 3-dimensional (3D) conformal results in hot spots (focal regions with dose variation greater than 10% of target); and
- The hot spots are able to be avoided with IMRT

#### Lung

Intensity-Modulated Radiotherapy of the lung is considered medically necessary when the following criteria is met:

- Radiotherapy is being given with curative intent;
- 3D conformal wall expose  $>35\%$  of normal lung tissue to more than 20 Gy dose-volume ( $V_{20}$ ); and
- IMRT dosimetry demonstrates reduction in the  $V_{20}$  to at least 10% below the  $V_{20}$  that is achieved with the 3D plan (e.g., from 40% down to 30% or lower).

## PRIOR AUTHORIZATION

### BlueCHiP for Medicare and Commercial Products

Prior authorization is recommended and obtained via the online tool for participating providers.

## POLICY STATEMENT

### BlueCHiP for Medicare and Commercial Products

#### Breast

Intensity-modulated radiotherapy may be considered medically necessary when the criteria above has been met.

IMRT of the breast is considered not covered for BlueCHiP for Medicare and not medically necessary for Commercial Products as a technique of partial-breast irradiation after breast conserving surgery and for IMRT of the chest wall as a technique of post-mastectomy irradiation because there is insufficient evidence to determine the effects of the technology on health outcomes.

### **Lung**

Intensity-modulated radiotherapy may be considered medically necessary when the criteria above has been met.

IMRT is considered not covered for BlueCHiP for Medicare and not medically necessary for Commercial Products as a technique to deliver radiation therapy in patients receiving palliative treatment for lung cancer because conventional radiation techniques are adequate for palliation.

### **COVERAGE**

Benefits may vary between groups and contracts. Please refer to the appropriate Benefit Booklet, Evidence of Coverage or Subscriber Agreement for applicable radiology benefits/coverage.

### **BACKGROUND**

For certain stages of many cancers, including breast and lung, randomized controlled trials have shown that postoperative RT improves outcomes for operable patients. Adding radiation to chemotherapy also improves outcomes for those with inoperable lung tumors that have not metastasized beyond regional lymph nodes.

### **Radiation Techniques**

#### **Conventional External Beam Radiotherapy**

Over the past several decades, methods to plan and deliver RT have evolved in ways that permit more precise targeting of tumors with complex geometries. Most early trials used 2-dimensional radiation therapy (2D-RT) treatment planning, based on flat images and radiation beams with cross-sections of uniform intensity that were sequentially aimed at the tumor along 2 or 3 intersecting axes. Collectively, these methods are termed conventional external beam radiation therapy (EBRT).

#### **Three-Dimensional Conformal Radiation**

Treatment planning evolved by using 3D images, usually from computed tomography (CT) scans, to delineate the boundaries of the tumor and discriminate tumor tissue from adjacent normal tissue and nearby organs at risk for radiation damage. Computer algorithms were developed to estimate cumulative radiation dose delivered to each volume of interest by summing the contribution from each shaped beam. Methods also were developed to position the patient and the radiation portal reproducibly for each fraction and immobilize the patient, thus maintaining consistent beam axes across treatment sessions. Collectively, these methods are termed 3D conformal radiation therapy (3D-CRT).

#### **Intensity-Modulated Radiotherapy**

Intensity-modulated radiotherapy, which uses computer software and CT and magnetic resonance imaging (MRI), offers better conformality than 3D-CRT, as it is able to modulate the intensity of the overlapping radiation beams projected on the target and to use multiple shaped treatment fields. Treatment planning and delivery are more complex, time consuming, and labor intensive for IMRT than for 3D-CRT. The technique uses a multileaf collimator (MLC), which, when coupled with a computer algorithm, allows for “inverse” treatment planning. The radiation oncologist delineates the target on each slice of a CT scan and specifies the target’s prescribed radiation dose, acceptable limits of dose heterogeneity within the target volume, adjacent normal tissue volumes to avoid, and acceptable dose limits within the normal tissues. Based on these parameters and a digitally reconstructed radiographic image of the tumor, surrounding tissues, and organs at

risk, computer software optimizes the location, shape, and intensities of the beam's ports to achieve the treatment plan's goals.

Increased conformality may permit escalated tumor doses without increasing normal tissue toxicity and thus may improve local tumor control, with decreased exposure to surrounding, normal tissues, potentially reducing acute and late radiation toxicities. Better dose homogeneity within the target may also improve local tumor control by avoiding underdosing within the tumor and may decrease toxicity by avoiding overdosing.

Technologic development has produced advanced techniques that may further improve RT treatment by improving dose distribution. These techniques are considered variations of IMRT. Volumetric modulated arc therapy (VMAT) involves delivery of radiation from a continuous rotation of the radiation source. The principal advantage of VMAT is greater efficiency in treatment delivery time, reducing radiation exposure and improving target radiation delivery due to less patient motion. Image-guided RT involves the incorporation of imaging before and/or during treatment to more precisely deliver RT to the target volume.

Multiple-dose planning studies generate 3-dimensional conformal radiotherapy (3D-CRT) and intensity modulated radiotherapy (IMRT) treatment plans from the same scans, and then compare predicted dose distributions within the target area and adjacent organs. Results of such planning studies show that IMRT improves on 3D-CRT with respect to conformality to, and dose homogeneity within, the target. They also demonstrate less radiation exposure to nontarget areas. Dosimetry studies using stationary targets generally confirm these predictions. However, because patients move during treatment, dosimetry with stationary targets only approximate actual radiation doses received. Based on these dosimetry studies, radiation oncologists expect IMRT to improve treatment outcomes compared with those of 3D-CRT. However, these types of studies offer only indirect evidence on treatment benefit from IMRT, and it is difficult to relate results of dosing studies to actual effects on health outcomes.

Comparative studies of radiation-induced adverse effects from IMRT versus alternative radiation delivery would constitute definitive evidence in establishing the benefit of IMRT. Single-arm series of IMRT can give some insights into the potential for benefit, particularly if an adverse effect that is expected to occur at high rates is shown to decrease by a large amount. Studies of treatment benefit are also important to establish that IMRT is at least as good as other types of delivery, but in the absence of such comparative trials, it is likely that benefit from IMRT is at least as good as with other types of delivery.

In general, when the indication for IMRT is to avoid radiation to sensitive areas, dosimetry studies have been considered sufficient evidence to demonstrate that harm would be avoided by using IMRT. For other indications for IMRT, such as using IMRT to provide better tumor control, comparative studies of health outcomes are needed to demonstrate such a benefit.

For individuals with breast cancer who receive IMRT, relevant outcomes are overall survival, disease progression, quality of life, and treatment-related morbidity. Studies on IMRT compared to 3D-CRT include one randomized controlled trial (RCT) on partial breast IMRT and one nonrandomized comparative study on whole-breast IMRT. These studies suggest that IMRT may improve short-term clinical outcomes. Longer follow-up is needed to evaluate the effect of partial breast IMRT on recurrence and survival. No studies have reported on health outcomes after IMRT for chest wall irradiation in postmastectomy breast cancer patients. Available studies have only focused on treatment planning and techniques. The risk of secondary lung cancers and cardiac toxicity needs to be further evaluated. The evidence is insufficient to determine the effects of the technology on health outcomes.

For individuals with lung cancer who receive IMRT, the evidence includes nonrandomized, retrospective, comparative studies. Relevant outcomes are overall survival, disease progression, quality of life, and treatment-related morbidity. Dosimetry studies report that IMRT can reduce radiation exposure to critical surrounding structures, especially in large lung cancers. However, based on nonrandomized comparative

studies, IMRT appears to produce survival outcomes comparable with that of 3D-CRT, with a reduction in adverse events. Interpretation is limited by the potential for bias in treatment assignment and/or change in treatments over time in these retrospective studies. The evidence is sufficient to determine the effects of the technology on health outcomes.

Some local medical review policies, published by Medicare Part B carriers, have indicated that IMRT for the lung is considered medically necessary. These documents do not provide a detailed rationale for this conclusion.

## **CODING**

### **BlueCHiP for Medicare and Commercial Products**

**A4648** Tissue marker, implantable, any type, each (Note: This code is not separately reimbursed for institutional providers.)

**Note:** To ensure correct pricing of HCPC code **A4648** for the Calypso 4D localization system, the procedure/clinical notes and the invoice must be submitted.

The following codes are covered for BlueCHiP for Medicare and Commercial products when the criteria above is met:

#### **Intensity-modulated radiation therapy**

**77301** Intensity modulated radiotherapy plan, including dose-volume histograms for target and critical structure partial tolerance specifications

**77338** Multi-leaf collimator (MLC) device(s) for intensity modulated radiation therapy (IMRT), design and construction per IMRT plan

**77385** Intensity modulated radiation treatment delivery (IMRT), includes guidance and tracking, when performed; simple (Institutional providers)

**77386** Intensity modulated radiation treatment delivery (IMRT), includes guidance and tracking, when performed; complex: (Institutional providers)

**G6015** Intensity modulated treatment delivery (IMRT), single or multiple fields/arcs, via narrow spatially and temporally modulated beams, binary, dynamic MLC, per treatment session: (Professional providers)

**G6016** Compensator-based beam modulation treatment delivery of inverse planned treatment using 3 or more high resolution (milled or cast) compensator, convergent beam modulated fields, per treatment session: (Professional providers)

## **RELATED POLICIES**

Preauthorization via Web-Based Tool for Procedures

Intensity Modulated Radiotherapy: Abdomen and Pelvis

Intensity Modulated Radiotherapy: Central Nervous System Tumors

Intensity Modulated Radiotherapy: Head, Neck and Thyroid Cancer

Intensity Modulated Radiotherapy: Prostate

## **PUBLISHED**

Provider Update, November/December 2018

Provider Update, October 2017

Provider Update, November 2016

Provider Update, February 2016

Provider Update, October 2015

## REFERENCES

1. Donovan E, Bleakley N, Denholm E, et al. Randomised trial of standard 2D radiotherapy (RT) versus intensity modulated radiotherapy (IMRT) in patients prescribed breast radiotherapy. *Radiother Oncol.* Mar 2007;82(3):254-264. PMID 17224195
2. Pignol JP, Olivetto I, Rakovitch E, et al. A multicenter randomized trial of breast intensity-modulated radiation therapy to reduce acute radiation dermatitis. *J Clin Oncol.* May 1 2008;26(13):2085-2092. PMID 18285602
3. Violet JA, Harmer C. Breast cancer: improving outcome following adjuvant radiotherapy. *Br J Radiol.* Oct 2004;77(922):811-820. PMID 15482992
4. Arthur DW, Morris MM, Vicini FA. Breast cancer: new radiation treatment options. *Oncology.* Nov 2004;18(13):1621-1629; discussion 1629-1630, 1636-1638. PMID 15648295
5. Coles CE, Moody AM, Wilson CB, et al. Reduction of radiotherapy-induced late complications in early breast cancer: the role of intensity-modulated radiation therapy and partial breast irradiation. Part II--Radiotherapy strategies to reduce radiation-induced late effects. *Clin Oncol.* Apr 2005;17(2):98-110. PMID 15830572
6. Formenti SC, Truong MT, Goldberg JD, et al. Prone accelerated partial breast irradiation after breast-conserving surgery: preliminary clinical results and dose-volume histogram analysis. *Int J Radiat Oncol Biol Phys.* Oct 1 2004;60(2):493-504. PMID 15380584
7. Alonso-Basanta M, MacDonald S, Lymberis S et al. Dosimetric comparisons of supine versus prone radiation: implications on normal tissue toxicity. *Int J Radiat Oncol Biol Phys.* 2005;63(2 suppl1):S182-183. PMID
8. Remouchamps VM, Vicini FA, Sharpe MB, et al. Significant reductions in heart and lung doses using deep inspiration breath hold with active breathing control and intensity-modulated radiation therapy for patients treated with locoregional breast irradiation. *Int J Radiat Oncol Biol Phys.* Feb 1 2003;55(2):392-406. PMID 12527053
9. Frazier RC, Vicini FA, Sharpe MB, et al. Impact of breathing motion on whole breast radiotherapy: a dosimetric analysis using active breathing control. *Int J Radiat Oncol Biol Phys.* Mar 15 2004;58(4):1041-1047. PMID 15001243
10. Chang JY, Liu HH, Komaki R. Intensity modulated radiation therapy and proton radiotherapy for non-small cell lung cancer. *Curr Oncol Rep.* Jul 2005;7(4):255-259. PMID 15946583
11. Dayes I, Rumble RB, Bowen J, et al. Intensity-modulated radiotherapy in the treatment of breast cancer. *Clin Oncol.* Sep 2012;24(7):488-498. PMID 22748561
12. Staffurth J. A review of the clinical evidence for intensity-modulated radiotherapy. *Clin Oncol.* Oct 2010;22(8):643-657. PMID 20673708
13. Donovan EM, Bleackley NJ, Evans PM, et al. Dose-position and dose-volume histogram analysis of standard wedged and intensity modulated treatments in breast radiotherapy. *Br J Radiol.* Dec 2002;75(900):967-973. PMID 12515705
14. Donovan EM, Yarnold JR, Adams EJ, et al. An investigation into methods of IMRT planning applied to breast radiotherapy. *Br J Radiol.* Apr 2008;81(964):311-322. PMID 18344275

15. Barnett GC, Wilkinson J, Moody AM, et al. A randomised controlled trial of forward-planned radiotherapy (IMRT) for early breast cancer: baseline characteristics and dosimetry results. *Radiother Oncol*. Jul 2009;92(1):34-41. PMID 19375808
16. Barnett GC, Wilkinson JS, Moody AM, et al. Randomized controlled trial of forward-planned intensity modulated radiotherapy for early breast cancer: interim results at 2 years. *Int J Radiat Oncol Biol Phys*. Feb 1 2012;82(2):715-723. PMID 21345620
17. McDonald MW, Godette KD, Butker EK, et al. Long-term outcomes of IMRT for breast cancer: a single-institution cohort analysis. *Int J Radiat Oncol Biol Phys*. Nov 15 2008;72(4):1031-1040. PMID 18440727
18. Vicini FA, Sharpe M, Kestin L, et al. Optimizing breast cancer treatment efficacy with intensity-modulated radiotherapy. *Int J Radiat Oncol Biol Phys*. Dec 1 2002;54(5):1336-1344. PMID 12459355
19. Selvaraj RN, Beriwal S, Pourarian RJ, et al. Clinical implementation of tangential field intensity modulated radiation therapy (IMRT) using sliding window technique and dosimetric comparison with 3D conformal therapy (3DCRT) in breast cancer. *Med Dosim*. Winter 2007;32(4):299-304. PMID 17980832
20. Hardee ME, Raza S, Becker SJ, et al. Prone hypofractionated whole-breast radiotherapy without a boost to the tumor bed: comparable toxicity of IMRT versus a 3D conformal technique. *Int J Radiat Oncol Biol Phys*. Mar 1 2012;82(3):e415-423. PMID 22019349
21. Ling DC, Hess CB, Chen AM, et al. Comparison of toxicity between intensity-modulated radiotherapy and 3-dimensional conformal radiotherapy for locally advanced non-small-cell lung cancer. *Clin Lung Cancer*. Jan 2016;17(1):18-23. PMID 26303127
22. Pignol JP, Truong P, Rakovitch E, et al. Ten years results of the Canadian breast intensity modulated radiation therapy (IMRT) randomized controlled trial. *Radiother Oncol*. Dec 2016;121(3):414-419. PMID 27637858
23. Chun SG, Hu C, Choy H, et al. Impact of intensity-modulated radiation therapy technique for locally advanced non-small-cell lung cancer: a secondary analysis of the NRG Oncology RTOG 0617 randomized clinical trial. *J Clin Oncol*. Jan 2017;35(1):56-62. PMID 28034064
24. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Breast Cancer. Version 2.2017. [http://www.nccn.org/professionals/physician\\_gls/pdf/breast.pdf](http://www.nccn.org/professionals/physician_gls/pdf/breast.pdf). Accessed June 11, 2017.
25. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Small Cell Lung Cancer. Version 3.2017. [http://www.nccn.org/professionals/physician\\_gls/pdf/sclc.pdf](http://www.nccn.org/professionals/physician_gls/pdf/sclc.pdf). Accessed June 11, 2017.

[CLICK THE ENVELOPE ICON BELOW TO SUBMIT COMMENTS](#)

This medical policy is made available to you for informational purposes only. It is not a guarantee of payment or a substitute for your medical judgment in the treatment of your patients. Benefits and eligibility are determined by the member's subscriber agreement or member certificate and/or the employer agreement, and those documents will supersede the provisions of this medical policy. For information on member-specific benefits, call the provider call center. If you provide services to a member which are determined to not be medically necessary (or in some cases medically necessary services which are non-covered benefits), you may not charge the member for the services unless you have informed the member and they have agreed in writing in advance to continue with the treatment at their own expense. Please refer to your participation agreement(s) for the applicable provisions. This policy is current at the time of publication; however, medical practices, technology, and knowledge are constantly changing. BCBSRI reserves the right to review and revise this policy for any reason and at any time, with or without notice. Blue Cross & Blue Shield of Rhode Island is an independent licensee of the Blue Cross and Blue Shield Association.

